Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
daratumumab + bortezomib + cyclophosphamide + dexamethasone
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Subcutaneous, Oral
01
Overview
This is a four-drug combination regimen consisting of daratumumab (a monoclonal antibody targeting CD38), bortezomib (a proteasome inhibitor), cyclophosphamide (an alkylating agent), and dexamethasone (a synthetic glucocorticoid corticosteroid). The regimen is primarily used as induction therapy for newly diagnosed or relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis. Daratumumab induces tumor cell death through immune-mediated mechanisms by binding to CD38 on plasma cells. Bortezomib inhibits the 26S proteasome, disrupting protein degradation and leading to apoptosis in malignant cells. Cyclophosphamide crosslinks DNA, inhibiting replication and transcription in rapidly dividing cells. Dexamethasone exerts anti-inflammatory and cytotoxic effects on lymphoid malignancies. This combination has demonstrated high response rates and improved progression-free survival in clinical trials for multiple myeloma and AL amyloidosis[2][6][8].
- Other names
- D-VCddara-CyBorDdaratumumab-CyBorD
02
Targets
CD38 (Cluster of Differentiation 38)DNAGR (Glucocorticoid receptor)PSMB5 (Proteasome subunit beta Type-5)
Beyond the preview
Go deeper on daratumumab + bortezomib + cyclophosphamide + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on daratumumab + bortezomib + cyclophosphamide + dexamethasone.